Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases

被引:30
|
作者
Lunkes, A
Trottier, Y
Mandel, JL
机构
[1] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France
[2] Hop Univ Strasbourg, Strasbourg, France
来源
ESSAYS IN BIOCHEMISTRY, VOL 33, 1998 | 1998年 / 33卷
关键词
D O I
10.1042/bse0330149
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
• HD is an autosomal dominant neurodegenerative disorder characterized by involuntary movements, cognitive impairment progressing to dementia, and mood disturbances. The brains of patients show extensive neuronal loss in the striatum, and the cerebral cortex is also affected. • The genetic defect causing HD is an expansion of a CAG repeat encoding a polyglutamine stretch in the target protein, named huntingtin. • The age of onset of HD is inversely correlated with the size of the expansion. • Polyglutamine expansion represents a novel cause of neurodegeneration, which has been shown to be responsible for seven other inherited disorders. • The polyglutamine expansion confers a gain of toxic property to the mutated target proteins. • Molecular and cellular studies of the brains of patients and of mice models of polyglutamine expansion diseases have led to the identification of abnormal intracellular inclusions representing aggregation of the mutated protein. However, the mechanism whereby such polyglutamine expansion leads to selective neuronal dysfunction and death is still puzzling.
引用
收藏
页码:149 / 163
页数:15
相关论文
共 50 条
  • [41] A proteomic approach to elucidate wild type huntingtin function(s) and Huntington's disease pathological mechanisms
    Savas, J. N.
    Makusky, A.
    Markey, S. P.
    Tanese, N.
    MOLECULAR & CELLULAR PROTEOMICS, 2006, 5 (10) : S201 - S201
  • [42] Mechanisms of neurodegeneration in Huntington's disease
    Gil, Joana M.
    Rego, Ana Cristina
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2008, 27 (11) : 2803 - 2820
  • [43] Mechanisms of neurodegeneration in Huntington's disease
    Gil, Joana M.
    Rego, Ana Cristina
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2008, 28 (10) : 2156 - 2156
  • [44] PATHOGENIC MECHANISMS IN HUNTINGTON'S DISEASE
    Jones, Lesley
    Hughes, Alis
    PATHOPHYSIOLOGY, PHARMACOLOGY, AND BIOCHEMISTRY OF DYSKINESIA, 2011, 98 : 373 - 418
  • [45] Polyglutamine expansion neurodegenerative disease
    Fischbeck, KH
    BRAIN RESEARCH BULLETIN, 2001, 56 (3-4) : 161 - 163
  • [46] POLYGLUTAMINE EXPANSION AS A PATHOLOGICAL EPITOPE IN HUNTINGTONS-DISEASE AND 4 DOMINANT CEREBELLAR ATAXIAS
    TROTTIER, Y
    LUTZ, Y
    STEVANIN, G
    IMBERT, G
    DEVYS, D
    CANCEL, G
    SAUDOU, F
    WEBER, C
    DAVID, G
    TORA, L
    AGID, Y
    BRICE, A
    MANDEL, JL
    NATURE, 1995, 378 (6555) : 403 - 406
  • [47] Polyglutamine-induced ion channels: A possible mechanism for the neurotoxicity of Huntington and other CAG repeat diseases
    Hirakura, Y
    Azimov, R
    Azimova, R
    Kagan, BL
    JOURNAL OF NEUROSCIENCE RESEARCH, 2000, 60 (04) : 490 - 494
  • [48] Huntington's disease-like 2: a clinical, pathological, and molecular comparison to Huntington's disease
    Margolis, RL
    Holmes, SE
    CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 187 - 196
  • [49] Axonal transport in polyglutamine-expansion diseases
    Brady, Scott T.
    Morfini, Gerardo
    Pigino, Gustavo
    Szebenyi, Gyorgyi
    You, Yimei
    Pollema, Sarah
    NEUROSCIENCE RESEARCH, 2006, 55 : S37 - S37
  • [50] Low cancer prevalence in polyglutamine expansion diseases
    Coarelli, G.
    Diallo, A.
    Calvas, F.
    Charles, P.
    Marelli, C. Tosi
    Ewenczyk, C.
    Tranchant, C.
    Tchikviladze, M.
    Monin, M-L
    Carlander, B.
    Anheim, M.
    Mochel, F.
    Brice, A.
    Du Montcel, S. Tezenas
    Humbert, S.
    Durr, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 38 - 38